KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in ReceivablesDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther financing activitiesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Inovio Pharmaceuticals (INO) Share-based Compensation (2016 - 2025)

Inovio Pharmaceuticals (INO) has disclosed Share-based Compensation for 16 consecutive years, with $764561.0 as the latest value for Q4 2025.

  • Quarterly Share-based Compensation fell 41.89% to $764561.0 in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $2.9 million through Dec 2025, down 46.0% year-over-year, with the annual reading at $3.8 million for FY2025, 43.05% down from the prior year.
  • Share-based Compensation hit $764561.0 in Q4 2025 for Inovio Pharmaceuticals, up from $742000.0 in the prior quarter.
  • In the past five years, Share-based Compensation ranged from a high of $9.6 million in Q1 2021 to a low of $40000.0 in Q3 2024.
  • Historically, Share-based Compensation has averaged $2.7 million across 5 years, with a median of $1.9 million in 2023.
  • Biggest five-year swings in Share-based Compensation: skyrocketed 1806.47% in 2021 and later crashed 97.89% in 2024.
  • Year by year, Share-based Compensation stood at $5.5 million in 2021, then crashed by 40.18% to $3.3 million in 2022, then crashed by 30.79% to $2.3 million in 2023, then plummeted by 41.94% to $1.3 million in 2024, then crashed by 41.89% to $764561.0 in 2025.
  • Business Quant data shows Share-based Compensation for INO at $764561.0 in Q4 2025, $742000.0 in Q3 2025, and $1.4 million in Q1 2025.